INSIDE LI LI

Role of hemidesmosomes in invasive squamous cell carcinoma
See page 1414
Stratified squamous epithelia serve important barrier functions in squamous mucosa and skin. To ensure integrity of the barrier, they are firmly anchored to the basal lamina by hemidesmosomes (HDs). Squamous cell carcinomas (SCCs) are invasive and aggressive cancers that arise mostly from stratified squamous epithelia. During invasion, neoplastic squamous cells invade through the basal lamina into adjacent soft tissue and blood vessels. This process is helped by the destruction of HDs, which might otherwise oppose invasion.
HDs are multiprotein assemblies containing α6β4 integrin, a protein with a central role in their maintenance. α6β4 integrin connects to laminin on the basal lamina and facilitates assembly of other HD components that eventually bind to cytokeratins. Phosphorylation of critical serine residues is known to alter β4 integrin function. On the basis of these data, Kashyap et al hypothesized that β4 integrin phosphorylation might alter HD stability during SCC invasion.
Using phospho-specific antibodies, the authors demonstrated that β4 integrin phosphorylation at serine 1356 correlated with SCC invasion in tissue sections. The pattern of phosphorylation was discontinuous and more prominent at the tumor-stroma interface, suggesting a causal relationship between β4 phosphorylation and invasion. They also showed that β4 phosphorylation was dependent on the epidermal growth factor/protein kinase C (EGF/PKC) pathway, although the EGF receptor appeared to have intrinsic activity that was not further stimulated by exogenous EGF. Finally, their findings suggest that, although HD destabilization is important for SCC invasion, it does not play an important role in SCC migration. In summary, this study demonstrates that HD destabilization through EGF/PKC signaling plays a critical role in SCC invasion.
Disease-defining translocation in nodular fasciitis
See page 1427
Nodular fasciitis (NF) is a common fibroblastic tumor that occurs predominantly in the extremities of adolescents and young adults. Although lesions grow rapidly and contain numerous mitotic figures, they regress if they are left untreated. This has led to vigorous debate about whether or not NF is a neoplasm.
While studying the expression patterns of USP6 (ubiquitin-specific protease 6), which encodes a de-ubiquitinating enzyme that is involved in a wide array of cellular processes and is expressed almost exclusively in testes, Erickson-Johnson et al found that USP6 was strongly expressed in NF. They showed that USP6 was fused to MYH9 (myosin heavy-chain 9), which encodes a member of the nonmuscle myosin class II family and is strongly expressed in fibroblasts. The fusions were predicted to express virtually fulllength USP6 from the noncoding exon 1 of MYH9. Thus, USP6 is overexpressed by a promoter-swapping mechanism whereby it is expressed via the MYH9 promoter, which in turn is strongly expressed in fibroblasts. USP6 and MYH9 gene rearrangements were found exclusively in NF; thus, the MYH9-USP6 gene fusion is disease defining for NF. When the authors injected a murine pre-osteoblastic cell line expressing USP6 subcutaneously into nude mice, tumors with the histologic features of NF grew but regressed within 2 to 3 weeks. These results strongly support that NF is a neoplasm-although one with a limited life span, leading the authors to suggest that NF represents the first reported example of what they call "limited neoplasia."
miRNA-148a suppresses tumor formation by targeting CDC25B
See page 1472 MicroRNAs (miRNAs), which exert their action by negatively regulating RNAs post-transcriptionally, are emerging as important oncogenes and tumor suppressors. Cancer-specific miRNAs are known as oncomiRs. miR-148a is downregulated in several types of solid cancers, suggesting that it is a tumor suppressor. To understand how it functions as a tumor suppressor, Liffers et al used an in silico approach to identify doi:10.1038/labinvest.2011.142 Laboratory Investigation (2011) 91, 1412-1413 © 2011 USCAP, Inc All rights reserved 0023-6837/11 $32.00 miR-148a targets that might be important in cancer initiation and progression in pancreatic adenocarcinoma.
There are several known targets of miR-148a, but the authors' analysis suggested that CDC25B is an additional target because it contains a putative miR148a binding site at the end of its 3′UTR. Reporter studies and overexpression studies showed that miR-148a reduces CDC25B levels, confirming that it is a target. CDC25 proteins are dual-specificity phosphatases that positively regulate cell cycle progression. CDC25B activates the CDK1/cyclin B complex at the G2/M checkpoint to initiate mitosis. Functional analysis showed that forced miR-148a expresson in a pancreatic cancer cell line reduced cell growth and proliferation, which is in keeping with the hypothesis that it acts by suppressing CDC25B. Furthermore, miR-148a suppressed expression of CDC25B in several pancreatic cancer cell lines. Evaluation of human tissues revealed that miR-148a levels were high in normal pancreatic epithelium and low in pancreatic adenocarcinoma precursors (PanINs) and pancreatic adenocarcinoma. Together these data led the authors to propose a model whereby repression of miR-148a by promoter hypermethylation is an early event in pancreatic adenocarcinoma carcinogenesis. The resultant increase in CDC25 facilitates increased genomic instability, resulting in the accumulation of oncogenic mutations that lead to tumor progression.
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Context is important for PICT1 function in cancer PICT1 has been thought to act as a tumor suppressor because it stabilizes PTEN and because low PICT1 expression is associated with tumor progression in some cancers. However, loss of heterozygosity at chromosome 19q13, the location of PICT1, is associated with good prognosis in oligodendroglial tumors. Sasaki et al, as recently reported in Nature Medicine, have resolved this apparent paradox. They demonstrated that PICT1 binds RP111, a nucleolar protein, which prevents it from binding MDM2, an E3 ubiquitin ligase that promotes p53 degradation. Thus, loss of PICT1 results in accumulation of p53. Although this does not affect cancers with inactivating p53 mutations, the response to increased p53 by cancers with functional p53 is decreased growth and increased apoptosis. It is therefore not surprising that loss of PICT1 is associated with a better prognosis in oligodendrogliomas, a tumor type characterized by a high percentage of cases with wild-type p53.
Brd4 controls oncogenesis in acute myeloid leukemia Epigenetic changes collaborate with a variety of oncogenic fusions to alter common core cellular processes that maintain a leukemic stem cell state in acute myelogenous leukemia (AML). As described in a recent letter in Nature, Zuber and colleagues used a customized RNA interference screen to identify epigenetic regulators that contribute to oncogenesis in AML. They identified Brd4, a member of the BET family of bromodomain-containing proteins that bind to acetylated histones to influence transcription, as important for cell survival. Targeting Brd4, either pharmacologically or by short hairpin RNA, caused terminal myeloid differentiation and elimination of AML stem cells through inhibition of Myc. The authors also demonstrated that Brd4 appears to influence Myc primarily in oncogenesis, suggesting that inhibition of Brd4 may be a good strategy to control oncogenic Myc. 
